Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $62 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Xenon Pharmaceuticals (NASDAQ:XENE), with a maintained price target of $62.
April 12, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Xenon Pharmaceuticals, with a maintained price target of $62.
The reiteration of a Buy rating by a reputable analyst, along with the maintenance of a significant price target, suggests a strong bullish sentiment towards Xenon Pharmaceuticals. This endorsement is likely to instill confidence in investors, potentially driving short-term positive momentum in the stock's price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100